A Study of IBI363 in Subjects With Advanced Melanoma
NCT06081920 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150
Last updated 2025-05-16
Summary
This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
Conditions
Interventions
- BIOLOGICAL
-
IBI363
IBI363 monotherapy
Sponsors & Collaborators
-
Innovent Biologics (Suzhou) Co. Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-10-19
- Primary Completion
- 2025-06-06
- Completion
- 2026-07-31
Countries
- China
Study Locations
More Related Trials
-
Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .
NCT04234620 ·Status: UNKNOWN
-
A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
NCT01654692 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII
NCT03818893 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients
NCT01990859 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
NCT01838200 ·Status: TERMINATED ·Phase: PHASE1
-
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
NCT04072900 ·Status: UNKNOWN ·Phase: PHASE1
-
Intratumoral Administration of L19IL2/L19TNF
NCT02076633 ·Status: COMPLETED ·Phase: PHASE2
-
AMT-253 in Patients With Advanced Solid Tumours
NCT06209580 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
NCT07280832 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma
NCT02738489 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
NCT03153085 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
NCT02821000 ·Status: COMPLETED ·Phase: PHASE1
-
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
NCT02581930 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT03021460 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma
NCT03696069 ·Status: COMPLETED
-
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
NCT06008106 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
NCT01783938 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
NCT06727630 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
NCT06566391 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
NCT02723006 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation
NCT05114603 ·Status: UNKNOWN ·Phase: PHASE2
-
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
NCT01621490 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
NCT01681212 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
NCT02970981 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
NCT01308762 ·Status: COMPLETED ·Phase: PHASE1